{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:44:58Z","timestamp":1788471898493,"version":"build-2803163510"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with limited consolidated evidence available from high-burden settings such as South Africa. Objectives: To systematically review and meta-analyse South African data on LZD and Pa resistance, minimum inhibitory concentrations (MICs), resistance-associated mutations, and treatment outcomes. Eligibility Criteria: We included clinical trials, cohort studies, surveillance studies, and molecular investigations conducted in South Africa from 2013 onward that reported resistance prevalence, MIC data, genotypic mutations, or treatment outcomes related to LZD and\/or Pa. Information Sources: PubMed, PubMed, Embase, Web of Science, and grey literature sources were searched from January 2013 to 31 December 2025 in accordance with PRISMA 2020 guidelines. Risk of Bias: Study quality was assessed using the Joanna Briggs Institute (JBI) cohort appraisal checklist. Included Studies: Seventeen studies representing provincial and national cohorts were included. Synthesis of Results: Random-effects meta-analysis was used to estimate pooled baseline resistance. Subgroup, sensitivity, and meta-regression analyses were performed. Results: Random-effects meta-analysis demonstrated a pooled baseline LZD resistance prevalence of 0.53% (95% CI: 0.01\u20131.83; I2 = 81.1%) in routine South African cohorts, while substantially higher resistance (33%) was observed in treatment-failure populations. Baseline LZD MICs were typically 0.125\u20131.0 \u00b5g\/mL, while elevated MICs (up to 8.0 \u00b5g\/mL) were associated with rplC and rrl mutations, particularly rplC Cys154Arg. No confirmed phenotypic Pa resistance was identified across included South African cohorts, despite the detection of resistance-associated mutations in genomic surveillance studies. MIC values remained within the range of 0.016\u20131.0 \u00b5g\/mL. Mutations in ddn, fbiA, fbiC, and fgd1 were reported in genomic studies. Treatment success rates ranged from 63.6% to 99% for LZD-containing regimens and approached 90% for Pa-based regimens. Limitations: Limited study numbers, heterogeneity in laboratory methods, and overrepresentation of certain provinces may affect generalizability. Conclusions: Baseline resistance to LZD and Pa in South Africa remains low, supporting continued programmatic use. Ongoing molecular surveillance is essential to detect resistance amplification and preserve regimen efficacy.<\/jats:p>","DOI":"10.3390\/antibiotics15060543","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:38:42Z","timestamp":1780411122000},"page":"543","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5351-7834","authenticated-orcid":false,"given":"Kabelo Gabriel","family":"Kaapu","sequence":"first","affiliation":[{"name":"Department of Pathology, School of Medicine, University of Limpopo, Sovenga 0727, Limpopo, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7676-2034","authenticated-orcid":false,"given":"Vukosi Treasure","family":"Makondo","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, University of Limpopo, Sovenga 0727, Limpopo, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-6620","authenticated-orcid":false,"given":"Emilyn","family":"Costa Concei\u00e7\u00e3o","sequence":"additional","affiliation":[{"name":"Division of Molecular Biology and Human Genetics, South African Medical Research Council Centre for Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town 7505, Western Cape, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivy","family":"Rukasha","sequence":"additional","affiliation":[{"name":"Department of Pathology, School of Medicine, University of Limpopo, Sovenga 0727, Limpopo, South Africa"},{"name":"Department of Microbiology, Polokwane Laboratory, National Health Laboratory Service, Polokwane 0699, Limpopo, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_2","unstructured":"World Health Organization (2026, March 11). WHO International [Internet]. 2024 Global Tuberculosis Report 2025. Available online: https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2025."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1801350","DOI":"10.1183\/13993003.01350-2018","article-title":"A new era for treatment of drug-resistant tuberculosis","volume":"52","author":"Gandhi","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_4","first-page":"130","article-title":"Multi-drug resistant tuberculosis","volume":"120","author":"Sharma","year":"2023","journal-title":"Bangladesh J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.2147\/IDR.S502302","article-title":"Treatment Outcomes for Drug-Resistant Tuberculosis Patients on Bedaquiline-Based Regimens in a Mostly Rural South Africa","volume":"18","author":"Rukasha","year":"2025","journal-title":"Infect. Drug Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S1473-3099(21)00811-2","article-title":"Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: A retrospective cohort study","volume":"22","author":"Ndjeka","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pai, H., Ndjeka, N., Mbuagbaw, L., Kaniga, K., Birmingham, E., Mao, G., Alquier, L., Davis, K., Bodard, A., and Williams, A. (2022). Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: A retrospective cohort analysis. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07861-x"},{"key":"ref_8","unstructured":"National Department of Health South Africa (2025, April 28). Introduction of BPaL-L, a 6-Month RR-TB Regimen.|Department of Health Knowledge Hub [Internet], Available online: https:\/\/knowledgehub.health.gov.za\/webinar\/introduction-bpal-l-6-month-rr-tb-regimen."},{"key":"ref_9","first-page":"70","article-title":"High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid","volume":"24","author":"Conradie","year":"2021","journal-title":"J. Int. AIDS Soc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/jac\/dkz206","article-title":"Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa","volume":"74","author":"Wasserman","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Timm, J., Bateson, A., Solanki, P., Paleckyte, A., Witney, A.A., Rofael, S.A.D., Fabiane, S., Olugbosi, M., McHugh, T.D., and Sun, E. (2023). Baseline and acquired resistance to bedaquiline, linezolid and pretomanid, and impact on treatment outcomes in four tuberculosis clinical trials containing pretomanid. PLoS Glob. Public Health, 3.","DOI":"10.1371\/journal.pgph.0002283"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.02012-19","article-title":"Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis","volume":"64","author":"Diacon","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1801528","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e02164-18","DOI":"10.1128\/AAC.02164-18","article-title":"Linezolid Pharmacokinetics in South African Patients with Drug-Resistant Tuberculosis and a High Prevalence of HIV Coinfection","volume":"63","author":"Wasserman","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.5588\/ijtld.20.0048","article-title":"Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid","volume":"24","author":"Padayatchi","year":"2020","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5588\/ijtld.21.0035","article-title":"Pretomanid with bedaquiline and linezolid for drug-resistant TB: A comparison of prospective cohorts","volume":"25","author":"Oelofse","year":"2021","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e0138121","DOI":"10.1128\/AAC.01381-21","article-title":"Linezolid Population Pharmacokinetics in South African Adults with Drug-Resistant Tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/jac\/dkac070","article-title":"Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid","volume":"77","author":"Bateson","year":"2022","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5588\/ijtld.21.0494","article-title":"Early mortality during rifampicin-resistant TB treatment","volume":"26","author":"Daniels","year":"2022","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e0291920","DOI":"10.1128\/JCM.02919-20","article-title":"Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): A 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Isolates","volume":"60","author":"Kaniga","year":"2022","journal-title":"J. Clin. Microbiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.2147\/IDR.S408976","article-title":"Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment","volume":"16","author":"Perumal","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/cid\/ciae145","article-title":"Treatment of Multidrug-resistant or Rifampicin-resistant Tuberculosis With an All-oral 9-month Regimen Containing Linezolid or Ethionamide in South Africa: A Retrospective Cohort Study","volume":"78","author":"Morgan","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/cid\/ciae614","article-title":"Diagnostic Accuracy of LiquidArray MTB-XDR VER 1.0 for the Detection of Mycobacterium tuberculosis Complex, Fluoroquinolone, Amikacin, Ethambutol, and Linezolid Susceptibility","volume":"81","author":"Auma","year":"2025","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Makondo, V.T., Kaapu, K.G., Wells, F., Sharma, A., Lekalakala-Mokaba, M.R., Warren, R., Concei\u00e7\u00e3o, E.C., and Rukasha, I. (2025). Empowering tuberculosis genomic surveillance in Limpopo, South Africa through capacity building. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1567382"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ngom, J.T., Loubser, J., Maasdorp, E., Ghebrekristos, Y., Singh, S., Opperman, C.J., Klopper, M., Warren, R.M., and Streicher, E.M. (2025). Population structure and emergence of resistance to new and repurposed drugs in XDR-TB: Insights from a 10-year genomic study in the Western Cape, South Africa review. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1638577"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cmi.2021.08.007","article-title":"Pretomanid for tuberculosis: A systematic review","volume":"28","author":"Gils","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1080\/14787210.2018.1472577","article-title":"Use of whole genome sequencing in surveillance of drug resistant tuberculosis","volume":"16","author":"McNerney","year":"2018","journal-title":"Expert. Rev. Anti-Infect. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijantimicag.2019.04.004","article-title":"Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand","volume":"54","author":"Faksri","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41579-019-0214-5","article-title":"Whole genome sequencing of Mycobacterium tuberculosis: Current standards and open issues","volume":"17","author":"Meehan","year":"2019","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"100128","DOI":"10.1016\/j.crphar.2022.100128","article-title":"Pretomanid for tuberculosis treatment: An update for clinical purposes","volume":"3","author":"Occhineri","year":"2022","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.5588\/ijtldopen.24.0360","article-title":"Efficacy and safety data on pretomanid for drug-resistant TB","volume":"2","author":"Thuy","year":"2025","journal-title":"IJTLD Open"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"106953","DOI":"10.1016\/j.ijantimicag.2023.106953","article-title":"Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice","volume":"62","author":"Nguyen","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5588\/ijtldopen.25.0677","article-title":"High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines","volume":"3","author":"Flores","year":"2026","journal-title":"IJTLD Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5588\/ijtld.23.0163","article-title":"Cost-effectiveness of pretomanid-based regimen for highly drug- resistant TB in a low-burden setting","volume":"28","author":"Fekadu","year":"2024","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"535","DOI":"10.5588\/ijtldopen.25.0294","article-title":"An economic analysis of BPaL for multidrug-resistant TB in South Africa and the Philippines","volume":"2","author":"Masuku","year":"2025","journal-title":"IJTLD Open"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/543\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:06:16Z","timestamp":1780412776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/6\/543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["antibiotics15060543"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15060543","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]}}}